Share on StockTwits

Regulus Therapeutics (NASDAQ:RGLS) Director Isis Pharmaceuticals Inc sold 2,600 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $6.21, for a total transaction of $16,146.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on RGLS shares. Analysts at Zacks upgraded shares of Regulus Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Tuesday, June 17th. They now have a $7.80 price target on the stock. Finally, analysts at Brinson Patrick initiated coverage on shares of Regulus Therapeutics in a research note on Tuesday, May 13th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $14.76.

Shares of Regulus Therapeutics (NASDAQ:RGLS) traded down 2.97% during mid-day trading on Friday, hitting $6.20. 64,548 shares of the company’s stock traded hands. Regulus Therapeutics has a 52 week low of $5.40 and a 52 week high of $11.88. The stock’s 50-day moving average is $7.22 and its 200-day moving average is $8.01. The company’s market cap is $268.8 million.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.16. On average, analysts predict that Regulus Therapeutics will post $-0.84 earnings per share for the current fiscal year.

Regulus Therapeutics Inc, is a biopharmaceutical company focused on discovering and developing microRNAs to treat a range of diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.